Literature DB >> 17136956

A two-stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral, and non-infectious origin of COPD exacerbations.

Roberto W Dal Negro1, Claudio Micheletto, Silvia Tognella, Marilia Visconti, Massimo Guerriero, Marco F Sandri.   

Abstract

UNLABELLED: Exacerbations often complicate the progressive course of chronic obstructive pulmonary disease (COPD), mainly due to infectious agents. The precise role of bacterial infections in the course and the pathogenesis of COPD has been a source of controversy for decades. Also viruses and other non-infectious causes of exacerbation play a relevant role and also contribute to persisting airway inflammation. Usually, the etiologic identification of the infective causes of COPD require considerable time and costs. The development of more rapid, reliable, and widely applicable methods to promptly define the etiology of COPD exacerbations should represent a relevant issue in devising earlier and more specific strategies for their effective therapeutic control. AIM: Of the study was to assess the predictive role of some pro-inflammatory cytokines measured in spontaneous bronchial secretions in discriminating the main infectious causes of COPD exacerbations.
METHODS: 124 subjects with moderate COPD (51-79 y; mean basal FEV1 = 49.6% pred. +/- 4.6 sd; FEV1 reversibility +3.9% from baseline +/- 4.8 sd after salbutamol 200 mcg) were studied during acute exacerbation. Respiratory viruses were isolated from bronchial secretions in 21 cases; common bacteria (CFU > or = 10(6)/ml) in 28 cases; Pseudomonas Aeruginosa (Ps.Ae.; CFU > or = 10(6)/ml) in 20 cases. The cytokines IL1beta, IL8, and TNFalpha (pg/ml; Immulite; Diagnostic Product Corp, Los Angeles, CA, USA), and neutrophils (% total count) were measured in bronchial secretions of all patients. STATISTICS: A two-stage logistic model was chosen for discriminating the different causes of COPD exacerbations (such as: non-infectious, or viral, bacterial, or due to Ps.Ae.).
RESULTS: At the first decisional step, the two-stage logistic model proved that TNFalpha levels in bronchial secretions recognise clearly patients belonging to the Ps.Ae. group from those of all other groups (Area under ROC curve = 0.96; 95% CI = 0.91-0.99), and that, at the second decisional step, IL8 + IL10 levels discriminate patients with bacterial causes (such as all bacteria) from the non-infected ones and from those with a viral cause of exacerbation (Area under ROC curve = 0.87; 95% CI = 0.77-0.94). Neutrophil percent count did not support any contribution in discriminating the different subgroups of COPD subjects.
CONCLUSIONS: When exacerbated, COPD subjects express different patterns of pro-inflammatory mediators in bronchial secretions, which appear modulated according to the etiological cause of the exacerbation. In particular, TNFalpha concentration per se enables recognition of COPD exacerbations due to Ps.Ae., while IL8 + IL1beta levels prove helpful in discriminating those to common bacteria from those to viral agents and to non-infectious causes. When present data are further confirmed, the use of a decisional rule based on cytokine measurements might be regarded as a helpful predictive tool. As measures of pro-inflammatory cytokines are low-cost, simple, and faster to perform, they could support rapid clinical decision making at the bedside regarding therapeutic strategy for COPD exacerbations, in particular when they are needed for severe COPD patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17136956     DOI: 10.1081/copd-200050680

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  11 in total

Review 1.  p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.

Authors:  Audreesh Banerjee; Cynthia Koziol-White; Reynold Panettieri
Journal:  Curr Opin Pharmacol       Date:  2012-02-24       Impact factor: 5.547

2.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

Review 3.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

Review 4.  Role of TNFalpha in pulmonary pathophysiology.

Authors:  Srirupa Mukhopadhyay; John R Hoidal; Tapan K Mukherjee
Journal:  Respir Res       Date:  2006-10-11

5.  A Simple Scoring System to Differentiate Bacterial from Viral Infections in Acute Exacerbations of COPD Requiring Hospitalization.

Authors:  Agustín Ruiz-González; Eduardo Sáez-Huerta; Montserrat Martínez-Alonso; Albert Bernet-Sánchez; José M Porcel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-04-08

Review 6.  Pulmonary biomarkers in COPD exacerbations: a systematic review.

Authors:  Angela Koutsokera; Konstantinos Kostikas; Laurent P Nicod; Jean-William Fitting
Journal:  Respir Res       Date:  2013-10-21

Review 7.  Cytokine inhibition in the treatment of COPD.

Authors:  Gaetano Caramori; Ian M Adcock; Antonino Di Stefano; Kian Fan Chung
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-04-28

8.  Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD.

Authors:  Antonino Di Stefano; Gaetano Caramori; Adam Barczyk; Chiara Vicari; Paola Brun; Andrea Zanini; Francesco Cappello; Elvira Garofano; Anna Padovani; Marco Contoli; Paolo Casolari; Andrew L Durham; Kian Fan Chung; Peter J Barnes; Alberto Papi; Ian Adcock; Bruno Balbi
Journal:  Thorax       Date:  2014-01-15       Impact factor: 9.139

Review 9.  Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations.

Authors:  Andrew I Ritchie; Jadwiga A Wedzicha
Journal:  Clin Chest Med       Date:  2020-09       Impact factor: 2.878

Review 10.  Personalized medicine for patients with COPD: where are we?

Authors:  Frits Me Franssen; Peter Alter; Nadav Bar; Birke J Benedikter; Stella Iurato; Dieter Maier; Michael Maxheim; Fabienne K Roessler; Martijn A Spruit; Claus F Vogelmeier; Emiel Fm Wouters; Bernd Schmeck
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.